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AbstrAct
Background Diagnostic accuracy is widely accepted 
by researchers and clinicians as an optimal expression 
of a test’s performance. The aim of this study was to 
evaluate the effects of disease severity distribution 
on values of diagnostic accuracy as well as propose a 
sample-independent methodology to calculate and display 
accuracy of diagnostic tests.
Methods and findings We evaluated the diagnostic 
relationship between two hypothetical methods to 
measure serum cholesterol (Chol
rapid and Cholgold) by 
generating samples with statistical software and (1) 
keeping the numerical relationship between methods 
unchanged and (2) changing the distribution of cholesterol 
values. Metrics of categorical agreement were calculated 
(accuracy, sensitivity and specificity). Finally, a novel 
methodology to display and calculate accuracy values was 
presented (the V-plot of accuracies).
Conclusion No single value of diagnostic accuracy can 
be used to describe the relationship between tests, as 
accuracy is a metric heavily affected by the underlying 
sample distribution. Our novel proposed methodology, 
the V-plot of accuracies, can be used as a sample-
independent measure of a test performance against a 
reference gold standard. 
IntroduCtIon
Almost all clinically useful biological meas-
urements are quantifiable continuous varia-
bles, such as arterial blood pressure, plasma 
glucose and serum cholesterol. For clinical 
convenience, however, many are interpreted 
qualitatively by a dichotomous classification 
into normal versus abnormal, based on a fixed 
cut-off. For instance, although serum levels of 
cholesterol can be quantified and displayed 
across a wide spectrum of values, patients are 
often labelled as having hypercholesterolaemia 
versus normal cholesterol based on an accepted 
cut-off value. Dichotomising results into posi-
tive versus negative is common in clinical 
practice because of the perceived pressure 
of information overload and with the reason 
given that often clinical decisions are them-
selves dichotomous (treat vs not treat, start or 
not a statin).
Qualitatively, the performance of a diag-
nostic test against a reference gold standard 
can be quantified by its diagnostic accuracy 
and the directly related sensitivity, specificity, 
predictive values, likelihood ratios and area under 
receiver operator characteristic (ROC) curve.1 
Among all such available measures, physi-
cians often choose diagnostic methods based 
on their published accuracy, a demonstration 
that statistical concepts can directly influ-
ence patient care and healthcare policies.2 
Key questions
What is already known about this subject?
Diagnostic methods are often chosen by clinicians 
based on their published diagnostic accuracy against 
a reference gold standard. The diagnostic accuracy of 
a method is known to be affected by the underlying 
disease prevalence.
What does this study add?
Using a practical example, we demonstrate how the 
pattern of disease severity distribution (intermediate vs 
extreme values) can affect the diagnostic accuracy of 
a method beyond disease prevalence. We propose the 
use of a novel V-plot of accuracies to display diagnostic 
accuracy values, which is a sample-independent, 
universal measure of a method’s categorical 
agreement with a reference standard.
How might this impact on clinical practice?
Using the V-plot of accuracies, researchers can 
describe the categorical agreement between two 
methods of measurement, and physicians may 
immediately appreciate the upper and lower limits of a 
test’s accuracy to decide which diagnostic method to 
choose for their patients.
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However, relying on a universal value of diagnostic accu-
racy as an idealised measure of a test’s performance is an 
approach with known limitations. First, accuracy values 
are known to depend on the prevalence of disease in the 
underlying sample, an extensively explored phenom-
enon.3 4 Second, beyond disease prevalence, how disease 
severity is distributed within a study sample independently 
affects a test’s accuracy, a phenomenon rarely discussed4 5 
and schematically explained in figure 1. For any given 
quantitative diagnostic method and its reference compar-
ison, diagnostic accuracy can have any value from approx-
imately 50% up to 100%; this value will depend on the 
numerical agreement between the methods (how good a 
test is) and also on whether the sample studied is formed 
by intermediate (close to cut-off) or extremes (away from 
cut-off) forms of disease.
In the present study, we aim to explore the specific 
effect of disease severity distribution on values of diag-
nostic accuracy and related statistical measures. As a solu-
tion, we propose the use of the accuracy V-plot, a novel, 
sample-independent method to calculate and present 
accuracy values.
MetHods
Hypothetical studies on a new method to measure serum 
cholesterol
This study used a hypothetical comparison between a new 
method to measure serum cholesterol (Cholrapid) and an 
established gold standard (Cholgold). The relationship 
between the two methods was compared in two different 
samples, artificially generated using statistical software 
(Mathworks, Natick, Massachusetts, USA):
1. Validation study sample: generated from 238 random 
values of cholesterol (Cholgold), not normally 
distributed, ranging from 2.9 mmol/L to 8.9 mmol/L, 
with a mean of 5.9 mmol/L.
2. Primary care, clinical study sample: generated from a 
narrower spread of 987 random, normally distributed 
values of cholesterol (Cholgold), ranging from 3.6 
mmol/L to 7.6 mmol/L, with a mean of 5.8 mmol/L 
and SD of 0.58 mmol/L.
In both samples 1 and 2, Cholrapid values were randomly 
generated keeping the mean difference with Cholgold 
close to 0 (0.05 mmol/L for sample 1 and 0.02 mmol/L 
for sample 2) and using a fixed SD of the difference 
Figure 1 Disease severity and classification agreement between methods: schematic representation of the principle that 
classification agreement between two methods of measurement (or diagnostic accuracy if one is seen as a reference gold 
standard) varies across the range of disease severity. At the extremes of disease and health agreement is 100%. Close to the 
classification cut-off, around the intermediate range of disease severity, agreement falls, reaching a nadir close to 50%.
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(SDD) between methods (SDD sample 1=0.36 mmol/L 
and SDD sample 2=0.35 mmol/L).
The relationship between the two methods (Cholrapid 
and Cholgold) was then compared in each sample using 
the following parameters:
1. Numerical relationship was evaluated using scatter 
plots and Bland-Altman plots.
2. Categorical relationship: diagnostic accuracy (or 
classification agreement between methods, defined 
as the total number of correctly classified data points 
divided by the total number of data points), sensitivity, 
specificity, positive and negative predictive values, 
positive and negative likelihood ratios and area under 
ROC curves. For the qualitative analysis, an arbitrary 
value of 5.7 mmol/L for Cholgold and Cholrapid values 
was defined as normal.
the V-plot of accuracies
We introduce a novel methodology to calculate and 
present classification agreement (accuracy) between 
methods, whereby the accuracy of Cholrapid is calculated 
and displayed across multiple quantiles of disease severity 
(from 2 to 10 mmol/L in 1 mmol/L bands). Finally, we 
proposed a method to estimate the accuracy of Cholrapid in 
independent samples in which the frequency distribution 
of Cholgold is known (a detailed stepwise approach to V-plot 
derivation is presented in figures 6 and 7).
results
The characteristics of the samples generated as well as 
the relationship between Cholrapid and Cholgold in each 
sample are presented as a series of hypothetical studies 
to facilitate the interpretation of our results into clinical 
practice.
A new diagnostic method for the screening of 
hypercholesterolaemia
Imagine investigators developed a new method to 
measure serum cholesterol that uses an infrared scan of 
the finger and yields an immediate value. The expecta-
tion was that this new test (Cholrapid) could be used in the 
primary care to screen for hypercholesterolaemia without 
the need for a needle or formal laboratory test and would 
enable identification of patients at high risk of cardiovas-
cular events and lead to early initiation of therapy.
An initial large validation study was required before its 
implementation in clinical practice, so Cholrapid had to be 
tested against the gold standard method of measuring 
cholesterol in the biochemistry laboratory (Cholgold). The 
validation study tested Cholrapid performance across a wide 
range of cholesterol values. Therefore, 238 patients were 
recruited from multiple clinical settings: healthy young 
volunteers with no history of cardiac disease, patients 
with multiple risk factors from a cardiovascular clinic and 
patients from a specialised hyperlipidaemia outpatient 
service. For the purpose of diagnostic classification, a 
cholesterol result of 5.7 mmol/Lor above was considered 
hypercholesterolaemia.
The results of this initial study confirmed early expecta-
tions, with Cholrapid showing an accuracy of 95% to diag-
nose hypercholesterolaemia, with a sensitivity of 95% and 
area under the ROC curve of 0.99 and positive and negative 
likelihood ratios of 23.75 and 0.05, respectively. Figure 2A 
summarises Cholrapid diagnostic performance.
As a result, Cholrapid was approved to be implemented in 
a large primary care unit for a period of trial. For 1 year, 
patients from the community with at least one risk factor 
for cardiovascular disease started having their cholesterol 
measured with Cholrapid. During this initial clinical evalu-
ation, however, blood samples were still sent for standard 
laboratory analysis (Cholgold), for a period of real-world 
comparison.
At the end of the first year of its utilisation, investigators 
re-evaluated Cholrapid diagnostic performance, comparing 
it against the same gold standard measurement Cholgold. 
The results of this second retrospective analysis were very 
disappointing. Cholrapid diagnostic accuracy to identify 
patients with hypercholesterolaemia fell to 83%, with 
a significant drop in sensitivity (84%), area under ROC 
curve (0.89) as well as a significant change in positive 
and negative likelihood ratios (4.4 and 0.2, respectively) 
(figure 2B). As a result, a primary care safety committee 
decided to temporarily withhold Cholrapid utilisation until 
a comprehensive assessment of its reliability was carried 
out.
The health authority looked into the reasons for such 
discrepancy between the final validation study and its first 
year of implementation but found nothing obvious: the 
technique applied was exactly the same, with compari-
sons made against Cholgold tested in the same biochem-
istry laboratory.
The fundamental relationship between Cholrapid and 
Cholgold remained unaltered in the two studies, as shown 
by the degree of vertical dispersion of values (raw measure-
ment disagreement) in both scatter plots (figure 3A). 
The stable relationship between the two methods can 
also be demonstrated in the form of Bland-Altman plots 
(figure 3B), which reveals that the 95% limits of agree-
ment were almost identical in the two studies.6
Therefore, the significant reduction in Cholrapid diag-
nostic performance between studies (accuracy, ROC 
curve, sensitivity and so on) can be entirely explained 
by how differently cholesterol values were distributed in 
the two samples (figure 4). The specific explanation is 
that the studies differed significantly in what proportion 
of patients had cholesterol values close to the diagnostic 
cut-off of 5.7 mmol/L; while the initial validation study 
included patients with a wide range of cholesterol values 
(and so a large proportion of them far away from the 
cutpoint), the primary care study was mainly formed by 
patients with intermediate values of cholesterol, strad-
dling the cut-off value, that is, the region where most 
disagreements occur. Differences in the distribution of 
cholesterol values, rather than in the actual measure-
ment performance of Cholrapid, were responsible for the 
different accuracy values (figure 1).
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the V-plot: a per-range display of accuracy values
To circumvent the sample dependency of overall accu-
racy values, instead of simply calculating an overall value 
of diagnostic accuracy for the whole study population, we 
propose to calculate the classification agreement between 
methods in each part of the spectrum of disease severity. 
This results in several per-quantile values of accuracies, 
which can be displayed across the entire range of disease 
severity to generate a V-shaped plot, which gives name to 
the method (figure 5). The V-plot has this shape because 
the accuracy of tests is universally high at the extremes of 
disease severity (near 100%) but close to the classification 
cut-off agreement plunges to around 50%. The width of 
the mouth of the V can be used as a general measure of 
a test’s performance: the wider the V, the poorer the test 
ability to match a reference modality.
The V-plot is, therefore, a universal fingerprint of 
per-quantile classification agreement between two 
methods of measurement, which can be expressed inde-
pendently of the distribution of values of the underlying 
sample. This can be demonstrated by displaying the 
V-plot from the two Cholrapid studies (figure 5). Despite 
marked differences in the distribution of cholesterol 
values and very different diagnostic accuracies, the 
V-plots from the two studies are almost identical. This 
can be interpreted as the two studies showing the same 
degree of classification agreement between Cholrapid 
and Cholgold across the spectrum of cholesterol values. 
Figure 6 explains in details the steps for the display of 
the V-plot and for the calculation of the overall accu-
racy in a sample.
using the V-plot to derive overall accuracy in independent 
samples
Once the V-plot has been established for the relationship 
between any two indices, the overall agreement between them 
can be projected to any other distribution of severity. For 
example, once a V-plot is derived from either of the two 
Cholrapid studies, it is possible to estimate the classification 
agreement between Cholrapid and Cholgold for a specialised 
outpatient lipid clinic, which is mainly formed by very high 
cholesterol levels (figure 7).
The simple mathematical approach to the applica-
tion of the V-plot is described in figure 6. We have also 
made a spread sheet available, which can derive the 
V-plot agreement between any two methods of measure-
ment and calculate the overall accuracy in samples with 
different distributions of values (online supplementary 
appendix).
Figure 2 Diagnostic performance of the new cholesterol test. The performance of the new cholesterol test (Cholrapid) changed 
significantly between the two studies. The overall accuracy of Cholrapid to diagnose hypercholesterolaemia fell in the primary 
care retrospective cohort (B), when compared with the initial validation study (A). Values of area under ROC curve, sensitivity, 
specificity and predictive values were also largely different. ROC, receiver operator characteristic.
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dIsCussIon
Choosing tests based on their reported accuracy
Classification agreement between two methods of 
measurement is called diagnostic accuracy if one test is 
considered the reference gold standard. The concept 
of accuracy is appealing, because it gives clinicians a 
standardised, dimensionless measure of how good a test 
is (the ideal test being 100% accurate).7 Neither meas-
ures of the vertical scatter in a correlation plot (the SE 
of the estimate, a measure of numerical disagreement) 
nor the calculation of limits of agreement using Bland-
Altman plots is as instantly appreciated by all clinicians. 
For instance, busy clinicians would much more confi-
dently adopt a test that is described as 95% accurate 
to detect hypercholesterolaemia than choose it based 
on a reported 0.35 mmol/L SE of the estimate against 
a reference method. However, our study demonstrates 
the limitations of adopting tests based on published 
high accuracy values, without knowing the sample from 
which accuracy was calculated.
disease distribution, disease prevalence and diagnostic 
accuracy
The impact of disease prevalence on diagnostic 
accuracy and derived metrics has been previously 
explored.4 8 It is widely perceived that diagnostic 
metrics more closely reflect a test’s performance 
when disease prevalence is near 50%.4 Our hypothet-
ical yet precisely controlled model of the relationship 
between two diagnostic methods brings interesting 
insights into this established statistical concept. First, 
our example confirms that accuracy, sensitivity, speci-
ficity and likelihood ratios are largely sample-dependent 
measures of a test performance. The values of all 
metrics changed largely between our two hypothet-
ical samples, with less discriminative values found in 
the normally distributed sample formed by interme-
diate values of cholesterol and disease prevalence of 
Figure 3 Numerical agreement between Cholrapid and Chogold is equal between studies. Despite different magnitudes of 
classification agreement (diagnostic accuracy) between Cholrapid and Cholgold in the two studies, the raw measurement 
disagreement between the two methods remained unchanged. This can be appreciated from measures of the vertical scatter 
such as the SE of the estimate (plot A) and from Bland-Altman plots (B). It can be inferred that the observed drop in Cholrapid 
performance in the primary care study cannot be explained by a change in its true measurement performance. LOA, limits of 
agreement.
Figure 4 Histograms of cholesterol values from both 
studies. While the validation study included patients with a 
wide range of cholesterol values, the primary care cohort 
was formed predominantly of patients with intermediate 
values of cholesterol. This difference was responsible for the 
significant drop in Cholrapid accuracy reported in the primary 
care study.
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50% (figure 2). Second, our results highlight that the 
precise distribution of values across the disease spec-
trum (and not only the overall prevalence of disease) 
is what predominantly affects values of accuracy and 
related metrics. For instance, a sample formed by very 
severely diseased and very healthy individuals, away 
from the central cut-off (in a ‘case-control’ fashion), 
is likely to derive very high values of accuracy (close 
to 100%) with a disease prevalence that can be close 
to 50%.9 10 In contrast, samples formed by interme-
diate values of disease, near the boundary between 
normal and abnormal, can also demonstrate 50% 
disease prevalence yet much lower values of accu-
racy (figure 1). In practice, mixtures of patients from 
these types, and other types in between, can generate 
any degree of diagnostic accuracy from 100% down to 
approximately 50% for all diagnostic tests and defini-
tions of severity.
disease severity distribution varies widely between studies
Studies that first evaluate diagnostic methods are often 
performed in samples whose distribution is very different 
from the populations in which the test will be applied in 
clinical practice.11 12 Commonly, pioneering research is 
performed in patients who either definitely have or defi-
nitely do not have a condition, in a case–control fashion 
or using a much wider spread of patients than is found in 
routine clinical practice.13 Values of accuracy and related 
parameters of a newly proposed methodology are univer-
sally presented, most commonly without a precise descrip-
tion of sample distribution of values. Rarely a frequency 
histogram is presented. While the desire to examine 
Figure 5 The V-plot of accuracies of Cholrapid. The V-plot permits a visual demonstration that the classification agreement 
between Cholrapid and Cholgold is equal in the two studies in each quantile of disease severity. The overall classification 
agreement (diagnostic accuracy of Cholrapid) could change between studies, depending on the proportion of patients in each 
quantile. The V-plot consistently identifies the range of cholesterol values within which the agreement between tests is lower 
than 90% (dashed lines).
 o
n
 22 July 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2017-000663 on 20 January 2018. Downloaded from
 
7Petraco R, et al. Open Heart 2018;5:e000663. doi:10.1136/openhrt-2017-000663
Basic and translational research
the whole spectrum is understandable, researchers may 
unknowingly be presenting values of a test accuracy that 
cannot be extrapolated to other studies nor are applicable 
to routine clinical practice. Physicians should realise that 
clinical populations often have substantially more patients 
in the middle zone, which inevitably lowers the accuracy 
of diagnostic methods.14 Therefore, for the relationship 
between any two methods of clinical measurement, there 
are no universal values of diagnostic accuracy, sensitivity, 
specificity, predictive values, ROC curves or even likelihood 
ratios. These parameters are only meaningful to demon-
strate the effects of the raw measurement disagreement 
between the two methods (vertical scatter; figure 3) in a 
specific sample when a specific classification cut-off is used 
to define what is normal/abnormal. Although the scien-
tific community emphasises the importance of studying 
new diagnostic methods in clinically relevant samples,2 5 
this matter is rarely debated when the accuracy of new 
diagnostic methods are published.15–17
Potential benefits of the V-plot of accuracies as a sample-
independent display of the relationship between methods
In this study, we introduced the V-plot of accuracies, 
a simple visual approach that could help researchers 
Figure 6 Methodology for the calculation of per-range agreement and V-plot display.
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and clinicians to better understand the relationship 
between diagnostic tests. First, the V-plot of accuracies 
allows interstudy comparisons, even if sample distri-
butions differ (figure 5). For instance, if a new diag-
nostic method to measure cholesterol is developed, 
its V-plot of per-range accuracy against Cholgold can be 
immediately derived and compared with the previously 
published V-plot of Cholrapid. While the values of overall 
accuracy may not be directly compared if samples are 
different, using the V-plot one can immediately appre-
ciate at which point within the spectrum of cholesterol 
values the diagnostic accuracy of the new cholesterol test 
falls below a certain standard. For instance, in our two 
studies, Cholrapid accuracy fell below 90% when choles-
terol values were between 5.2 mmol/L and 6.3 mmol/L 
(figure 5). In practice, therefore, outside this window, 
Cholrapid could be seen as >90% reliable and used for 
clinical decision making, while Cholgold might still be 
requested in the 5.2–6.3 mmol/L uncertainty zone to 
confirm the diagnosis. Such hybrid approach to clin-
ical diagnosis (trusting screening tests when results 
are very normal or very abnormal but requesting the 
gold standard in the middle zone) is often used in 
clinical practice instinctively.18 Our proposed V-plot 
methodology permits a formal statistical representa-
tion of such staged approach by establishing ranges 
of values outside which tests can be trusted to match a 
gold standard.
Also, as presented in figure 7, once one V-plot between 
methods has been established, the overall accuracy of the 
new test can be derived in any given sample, providing the 
frequency distribution of values is known. This method 
to derive overall accuracy in independent samples from a 
previous established V-plot is potentially useful if researchers 
or clinicians want to estimate the overall performance of new 
modalities without the need to collect new comparative data.
online appendix for V-plot derivation
We have created an online appendix in Excel format to 
allow readers to apply the V-plot methodology to their 
own datasets. Readers can adapt the calculation steps to 
their needs and add CIs to each quantile accuracy.
Alternative derivations and future work on methodology
The V-plot of accuracies could be displayed in two 
alternative ways. First, the average between methods 
could be used to define disease range (the x-axis on 
the V-plot), if they are both felt to measure exactly the 
Figure 7 Calculating the overall accuracy in different samples using the V-plot. The V-plot agreement between Cholrapid 
and Cholgold can be derived from any study that compared the two methods (top panel). It can be used as a fingerprint of 
classification agreement to calculate the overall agreement between Cholrapid and Cholgold in any sample in which the distribution 
of cholesterol values is known (samples A, B and C).
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same quantity, in line with Bland-Altman plots. In our 
example, average values between Cholrapid and Cholgold 
could be used instead of Cholgold only. The limitation of 
such approach is that frequency distribution of values 
are normally presented using histograms of the estab-
lish method and not the average between the two tests, 
which would limit the applicability of the V-plot to other 
samples. Second, the new method could be used in 
x-axis to define the range and quantiles (Cholrapid in our 
example). This would allow a more directly applicable 
display of results as, in practice, clinicians are first faced 
with the results of the new test (before requesting the 
reference method if felt necessary). In our example, if 
the per-range accuracy of Cholrapid was displayed using 
the Cholrapid range of values in the x-axis, one would 
immediately appreciate at which point close to its cut-off 
it starts losing accuracy against Cholgold. This approach 
would also permit interstudy comparisons between 
different methods, providing the gold standard meth-
odology was the same.
We specifically did not display CIs for each individual 
quantile accuracy. First, the aim of the V-plot was not to 
detect with precision each quantile accuracy, but instead 
to use the trend between quantiles to establish an overall 
pattern of accuracy loss from the extremes towards the 
intermediate range close to the cut-off. Second, the trend 
from the V-plot line between neighbouring quantiles act 
as external validity for each quantile accuracy, beyond the 
small sample of each quantile. As a result, to avoid over-
load of information to readers, we opted not to display 
CIs for each quantile when we first applied the method-
ology in real datasets.14 We have published an alternative 
V-plot methodology using logistical regression that derive 
95% CIs using bootstrap.19 However, logistical regression 
is a modelling approach with intrinsic limitations, while 
the methodology presented in this manuscript is derived 
from accuracy values directly calculated in each quantile. 
Researchers can easily add CIs for each quantile in the 
spreadsheet provided (online supplementary appendix), 
simply by treating each quantile accuracy as a proportion 
and applying simple statistics.
limitations
The V-plot is intended to display accuracy values of a new 
method of measurement when quantitative variables are 
categorically transformed into normal and abnormal 
according to a pre-established cut-off. It is therefore 
essential for least one of the methods to be numerical so 
that its range of values can be displayed in the x-axis.
The V-plot describes the accuracy of a new diagnostic 
test to categorically match a reference method. Therefore, 
it assumes the ‘gold standard’ test to be an appropriate 
and reliable representation of the underlying variable 
being measured (in our example serum cholesterol).
Also, although the present hypothetical study used an 
example in which the numerical relationship between 
methods was constant across the disease spectrum 
(homoscedasticity assumption), the V-plot methodology 
could also be applied to data when heteroscedasticity is 
found.
How to deal with quantiles with no data points? If a 
quantile has no data at the extremes of the distribution, 
investigators could simply (1) not display the V-plot values 
at that range or (2) assume in a reasonably normally 
distributed sample without major heteroscedasticity that 
the accuracy in that range will remain 100% if it is already 
100% in the immediately neighbour inner range (such as 
for cholesterol values below 3 in our figure 6). If a quan-
tile has no data points in the middle of the disease distribu-
tion, then investigators could (1) increase their sample 
size, (2) decrease the number of quantiles being used, 
so that the absent quantile becomes merged with neigh-
bour quantiles or (3) visually interpolate the V-plot line 
between the neighbouring quantiles, assuming accuracy 
in the absent quantile will be roughly the average of its 
neighbours.
This study is based on a hypothetical research scenario, 
and the data were created using statistical software. While 
this approach has limitations as data were not actually 
collected from patients, it allowed for a precise isola-
tion of statistical parameters of interest and permitted 
a very focused analysis of the effects of data distribution 
on accuracy values. The V-plot methodology has already 
been applied to real data previously.14 19
The present study does not aim to discuss the clin-
ical merits of cholesterol treatment neither the appro-
priateness of using a fixed cut-off for clinical decision 
making. The hypothetical clinical scenario of a new test 
to measure cholesterol was chosen to illustrate a prac-
tical application of our methodology to a wide clinical 
readership.
ConClusIons
For any given clinical test being compared with a gold 
standard, there is no universal value of diagnostic accu-
racy, sensitivity, specificity, predictive values, likelihood 
ratios or ROC curves. Accuracy will always vary progres-
sively from almost 100% at the extremes (of health and 
disease) to approximately 50% (close to pure chance) 
near the diagnostic cut-point. Disease prevalence and the 
precise distribution of values in the underlying sample 
(extremes versus intermediate) can therefore completely 
control the obtained value for a test’s diagnostic accu-
racy. A test should not be chosen by clinicians based on a 
reported high accuracy value, unless the disease distribu-
tion of the study sample is known to be clinically relevant.
The V-plot of accuracies presented here exposes the 
variation of diagnostic accuracy along the spectrum of 
disease and is therefore a truly sample-independent 
display of categorical agreement between two methods 
of clinical measurement. Once derived for the relation-
ship between two methods of measurement, the V-plot 
allows for the overall diagnostic accuracy to be estimated 
in separate samples where frequency distribution is 
known.
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